• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.

作者信息

Ahmed Ali, Blackman Marc R, White Michel, Anker Stefan D

机构信息

Veterans Affairs Medical Center, Washington, DC, USA.

George Washington University, Washington, DC, USA.

出版信息

Eur J Heart Fail. 2017 Sep;19(9):1198-1200. doi: 10.1002/ejhf.884. Epub 2017 May 30.

DOI:10.1002/ejhf.884
PMID:28560824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7887704/
Abstract
摘要

相似文献

1
Emphasis on abdominal obesity as a modifier of eplerenone effect in heart failure: hypothesis-generating signals from EMPHASIS-HF.强调腹部肥胖作为依普利酮治疗心力衰竭疗效的修饰因素：来自依普利酮治疗心力衰竭疗效及生存研究（EMPHASIS-HF）的假设生成信号
Eur J Heart Fail. 2017 Sep;19(9):1198-1200. doi: 10.1002/ejhf.884. Epub 2017 May 30.
2
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.依普利酮对射血分数降低的心力衰竭患者的影响：来自 EMPHASIS-HF 试验的潜在效应修饰因素分析。
Eur J Heart Fail. 2017 Sep;19(9):1186-1197. doi: 10.1002/ejhf.792. Epub 2017 Mar 16.
3
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).在心衰患者接受最佳医学治疗的基础上，加用盐皮质激素受体拮抗剂依普利酮或安慰剂，观察高钾血症和肾功能恶化的发生率、决定因素及其对预后的影响：依普利酮在轻中度心衰患者住院和生存研究（EMPHASIS-HF）的结果。
Circ Heart Fail. 2014 Jan;7(1):51-8. doi: 10.1161/CIRCHEARTFAILURE.113.000792. Epub 2013 Dec 2.
4
Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).依普利酮在高血钾风险和/或肾功能恶化患者中的安全性和疗效：EMPHASIS-HF 研究亚组分析（心力衰竭患者依普利酮住院和生存研究）。
J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93. doi: 10.1016/j.jacc.2013.04.086. Epub 2013 Jun 27.
5
Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.依普利酮在已接受最佳标准药物治疗的收缩性心力衰竭轻症患者中的临床获益： EMPHASIS-HF 研究分析。
Circ Heart Fail. 2013 Jul;6(4):711-8. doi: 10.1161/CIRCHEARTFAILURE.112.000173. Epub 2013 Apr 26.
6
A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.心肌梗死后心力衰竭中醛固酮拮抗剂的临床疗效和成本效果的系统评价和经济评估。
Health Technol Assess. 2010 May;14(24):1-162. doi: 10.3310/hta14240.
7
Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).射血分数保留的心力衰竭（HFpEF）中的盐皮质激素受体拮抗剂
Int J Cardiol. 2015 Dec 1;200:15-9. doi: 10.1016/j.ijcard.2015.07.038.
8
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.阿司匹林并不会降低矿皮质激素受体拮抗剂依普利酮在收缩性心力衰竭伴轻度症状患者中的临床获益：来自 EMPHASIS-HF 研究的分析。
Eur J Heart Fail. 2016 Sep;18(9):1175-81. doi: 10.1002/ejhf.485. Epub 2016 Feb 2.
9
Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).依普利酮和轻度心力衰竭患者新发糖尿病：心力衰竭患者依普利酮住院和生存研究（EMPHASIS-HF）的结果。
Eur J Heart Fail. 2012 Aug;14(8):909-15. doi: 10.1093/eurjhf/hfs067. Epub 2012 May 19.
10
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.依普利酮拮抗盐皮质激素受体的分子机制。
Mini Rev Med Chem. 2005 Aug;5(8):709-18. doi: 10.2174/1389557054553811.

引用本文的文献

1
Physical multimorbidity and dynapenic abdominal obesity among older adults from low- and middle-income countries.低收入和中等收入国家老年人的身体多重疾病与动态腹部肥胖
Commun Med (Lond). 2025 Jul 29;5(1):315. doi: 10.1038/s43856-025-01037-9.
2
Cardiovascular Imaging in Obesity.肥胖症的心血管影像学
Nutrients. 2021 Feb 26;13(3):744. doi: 10.3390/nu13030744.
3
Updates in heart failure: what last year brought to us.心力衰竭的最新进展：去年带给我们的内容
ESC Heart Fail. 2018 Dec;5(6):989-1007. doi: 10.1002/ehf2.12385.
4
The Impact of Obesity on the Cardiovascular System.肥胖对心血管系统的影响。
J Diabetes Res. 2018 Nov 4;2018:3407306. doi: 10.1155/2018/3407306. eCollection 2018.

本文引用的文献

1
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.依普利酮对射血分数降低的心力衰竭患者的影响：来自 EMPHASIS-HF 试验的潜在效应修饰因素分析。
Eur J Heart Fail. 2017 Sep;19(9):1186-1197. doi: 10.1002/ejhf.792. Epub 2017 Mar 16.
2
Interpreting Geographic Variations in Results of Randomized, Controlled Trials.解读随机对照试验结果中的地域差异
N Engl J Med. 2016 Dec 8;375(23):2263-2271. doi: 10.1056/NEJMra1510065.
3
Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats.预防性和慢性盐皮质激素受体拮抗作用对肥胖的SHHF大鼠非常有益。
Br J Pharmacol. 2016 Jun;173(11):1805-19. doi: 10.1111/bph.13479. Epub 2016 Apr 26.
4
Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking.长期戒烟后心力衰竭和死亡风险：既往吸烟量及持续时间的作用
Circ Heart Fail. 2015 Jul;8(4):694-701. doi: 10.1161/CIRCHEARTFAILURE.114.001885. Epub 2015 Jun 2.
5
Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure.慢性轻度至中度心力衰竭门诊患者的基础收缩压与长期结局的关系。
Am J Cardiol. 2011 Apr 15;107(8):1208-14. doi: 10.1016/j.amjcard.2010.12.020. Epub 2011 Feb 4.
6
Eplerenone in patients with systolic heart failure and mild symptoms.依普利酮治疗有收缩性心力衰竭和轻度症状的患者。
N Engl J Med. 2011 Jan 6;364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14.
7
The role of aldosteronism in causing obesity-related cardiovascular risk.醛固酮在导致肥胖相关心血管风险中的作用。
Cardiol Clin. 2010 Aug;28(3):517-27. doi: 10.1016/j.ccl.2010.04.001.
8
Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial).基线收缩压对晚期慢性收缩性心力衰竭患者长期结局的影响（来自 BEST 试验的见解）。
Am J Cardiol. 2010 Jul 15;106(2):221-7. doi: 10.1016/j.amjcard.2010.02.032.
9
Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study.老年单纯收缩期高血压与新发心力衰竭：一项倾向匹配研究。
Hypertension. 2009 Mar;53(3):458-65. doi: 10.1161/HYPERTENSIONAHA.108.119792. Epub 2009 Feb 2.
10
Plasma aldosterone and its relationships with left ventricular mass in essential hypertensive patients with the metabolic syndrome.原发性高血压合并代谢综合征患者的血浆醛固酮及其与左心室质量的关系。
Am J Hypertens. 2008 Sep;21(9):1055-61. doi: 10.1038/ajh.2008.225. Epub 2008 Jun 26.